- AU$11.95m
- AU$2.93m
- AU$7.71m
Brief: Immuron Announces Chairman Transition
Brief: Immuron Approves Imm-529 CGMP Manufacturing And To Proceed With FDA Pre-Ind Submission
Brief: Immuron Initiates Recruitment Of Travelan Clinical Study
Immuron up as FDA lifts hold on diarrhoea drug trial
Immuron surges as FDA lifts hold on diarrhoea drug trial
Brief: Immuron Says U.S. FDA Removed Clinical Hold On New Campylobacter ETEC Therapeutic IND Application
Brief: Immuron Evaluating Options To Enter Asian And European Markets Through Distributors
Brief: Immuron Q3 Sales Reach 150% Of 1H Sales
Australia's Immuron gains as Q3 sales more than triple
Brief: Immuron Says Global Q3 YTD FY23 Sales Of A$1.46 Million
Advisory: Incorrectly tagged alerts on Technology Metals Australia withdrawn
Advisory: Incorrectly tagged alerts on Technology Metals Australia withdrawn
Brief: Technology Metals Australia Says Engaged GR Engineering Service And Iron Mine Contracting
Brief: Immuron U.S. DoD Naval Medical Research Center Responds To FDA Clinical Hold
Brief: Immuron Receives FDA Approval For Travelan IND Application
Brief: Immuron Says Receives FDA Approval For Travelan Ind Application
Australia's Immuron rises on U.S. FDA nod for drug
Brief: Immuron Submits IND Application To FDA For Travelan
Australia's Immuron rises on diarrhoea drug application in U.S.